SCHEMBL3601537

SCHEMBL3601537

Nc1ccc(C(F)(F)F)c2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.46
EP300 Q09472 2/20 0.46
KAT8 Q9H7Z6 2/20 0.46
HDAC3 O15379 1/20 0.46
KAT2B Q92831 1/20 0.46
NCOR2 Q9Y618 1/20 0.46
ALDH1A1 P00352 4/20 0.46
HPGD P15428 3/20 0.46
HSD17B10 Q99714 3/20 0.46
TDP1 Q9NUW8 3/20 0.46
TSHR P16473 3/20 0.46
CYP3A4 P08684 2/20 0.46
BACE1 P56817 1/20 0.44
CHEK1 O14757 1/20 0.42
NEK2 P51955 1/20 0.42
LIMK1 P53667 1/20 0.42
DYRK1A Q13627 1/20 0.42
CLK4 Q9HAZ1 1/20 0.42
MEN1 O00255 3/20 0.40
MAPT P10636 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4082855 0.86 ALDH1A1 (0.59) IDO1ALDH1A1HPGDHSD17B10TDP1
SCHEMBL3756921 0.77 IDO1 (0.47) IDO1EP300KAT8HDAC3KAT2B
SCHEMBL201893 0.77 ALDH1A1 (0.73) IDO1EP300KAT8HDAC3KAT2B
SCHEMBL29404342 0.77 ALDH1A1 (0.73) IDO1EP300KAT8HDAC3KAT2B
SCHEMBL3327 0.74 CYP11B2 (0.40) ALDH1A1TDP1TSHRBACE1MEN1
SCHEMBL15958515 0.74 ALDH1A1 (0.39) ALDH1A1TDP1TSHRBACE1CLK4
Hydrochloric Acid SCHEMBL7191297 0.74 CYP3A4 (0.69) IDO1EP300KAT8HDAC3KAT2B
SCHEMBL21409791 0.74 ALDH1A1 (0.54) IDO1ALDH1A1HPGDHSD17B10TDP1
SCHEMBL5660868 0.74 AXL (0.50) EP300KAT8KAT2BALDH1A1CYP3A4
SCHEMBL690525 0.73 CYP3A4 (0.52) IDO1EP300KAT8HDAC3KAT2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170216283-A1 COMPOUNDS AND USES ASTRAZENECA AB (SE) 2017-08-03 US disclosed
US-20170216283-A1 COMPOUNDS AND USES ASTRAZENECA AB (SE) 2017-08-03 US disclosed
US-20170216283-A1 COMPOUNDS AND USES ASTRAZENECA AB (SE) 2017-08-03 US disclosed
US-9657001-B2 Compounds and uses ASTRAZENECA AB (SE) 2017-05-23 US disclosed
US-9657001-B2 Compounds and uses ASTRAZENECA AB (SE) 2017-05-23 US disclosed
US-9657001-B2 Compounds and uses ASTRAZENECA AB (SE) 2017-05-23 US disclosed
US-20160326143-A1 COMPOUNDS AND USES ASTRAZENECA AB (SE) 2016-11-10 US disclosed
US-20160326143-A1 COMPOUNDS AND USES ASTRAZENECA AB (SE) 2016-11-10 US disclosed
WO-2016177845-A1 CYCLOPROPANE CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL USES THEREOF ASTRAZENECA AB (SE) 2016-11-10 WO disclosed
US-20160326143-A1 COMPOUNDS AND USES ASTRAZENECA AB (SE) 2016-11-10 US disclosed
EP-1553074-B1 FUSED BENZENE DERIVATIVE AND USE TAKEDA PHARMACEUTICAL (JP) 2014-06-18 EP disclosed
US-20100048636-A1 Aspartic Protease Inhibitors VITAE PHARMACEUTICALS, INC. 2010-02-25 US disclosed
US-7649001-B2 Fused benzene derivative and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-19 US disclosed
US-7482339-B2 2-Naphthylimino-1,3-thiazine derivative SHIONOGI AND CO., LTD. (JP) 2009-01-27 US disclosed
US-20060281738-A1 2-Naphthylimino-1,3-thiazine derivative SHIONOGI AND CO., LTD. (JP) 2006-12-14 US disclosed
EP-1659117-A1 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2006-05-24 EP disclosed
US-20060106067-A1 Fused benzene derivative and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-05-18 US disclosed
EP-1553074-A1 FUSED BENZENE DERIVATIVE AND USE Takeda Pharmaceutical Company Limited (JP) 2005-07-13 EP disclosed
US-4731450-A Process for perfluoroalkylation of aromatic derivatives RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1988-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048636-A1 Aspartic Protease Inhibitors DNPEP, PEPD, SERPINB1 IDO1 619/4885EP300 2778/4885KAT8 4150/4885
US-20170216283-A1 COMPOUNDS AND USES LTC4S, LTB4R2, LTA4H IDO1 543/4885EP300 2184/4885KAT8 3086/4885
US-20060106067-A1 Fused benzene derivative and use AR, NR5A1, CBR3 IDO1 2261/4885EP300 1192/4885KAT8 2379/4885
US-20060281738-A1 2-Naphthylimino-1,3-thiazine derivative NPM1, OXTR, CYP2S1 IDO1 600/4885EP300 1212/4885KAT8 2260/4885
US-20160326143-A1 COMPOUNDS AND USES LTC4S, LTB4R2, LTA4H IDO1 543/4885EP300 2184/4885KAT8 3086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.